Subscribe to Entrepreneur for $5
Subscribe

Moderna's vaccine is safe and effective according to the FDA and could be approved this week

Two days before its approval for distribution is discussed, the U.S. Food and Drug Administration gave a positive rating to the company's COVID-19 drug.

By
This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.

After approving the COVID-19 vaccine from Pfizer-BioNTech , the United States Food and Drug Administration (FDA) reported that the vaccine from the American pharmaceutical company Moderna is safe and effective. The drug could receive authorization for distribution this week, when experts meet to discuss its emergency approval.

Reuters vía BI

The FDA confirmed that Moderna's vaccine does not show "specific safety concerns" in adults 18 years of age and older that "prevent the issuance" of an emergency use authorization.

"The FDA has determined that the manufacturer has provided adequate information to guarantee the quality and consistency of the vaccine for product authorization , " reads the document delivered by the US agency .

The reported efficacy among study participants was 94.5%, and 100% for those over 65 years of age. That is, none of the 3,527 volunteers in this age group had contagion. Among the 10,407 people aged 18 to 65 studied, there were 5 positives. None of them developed a severe COVID-19 picture.

Moderna Vaccine Has "Mild" Side Effects

The formula, called mRNA-1273 , presented some side effects such as pain at the injection site (90% of cases), fatigue (70%), headache (60%), muscle pain (60%), pain joint (45%) and chills (45%). Few of these effects were "serious" and occurred more in the young than in older adults. Lymphadenopathy , or swollen lymph nodes, occurred in 1.1% of those vaccinated, in contrast to 0.6% of the group that received the placebo.

1.5% of the vaccinated population presented "hypersensitivity" , that is, allergic or inflammatory reactions of the immune system. In comparison, 1.1% of the unvaccinated reported such a reaction.

The FDA report is part of the documents released for Thursday's meeting, where experts will debate whether to approve an emergency use authorization for Moderna's vaccine.

The Pfizer and BioNTech vaccine was approved on Friday night, after the committee approved the formula by broad consensus the day before, which began to be applied this Monday in the United States.

The United States plans to supply 40 million doses of vaccine this month, enough to inoculate 20 million people. That includes both the Pfizer-BioNTech and Moderna vaccines, which would be the second available formula to fight the SARS-CoV-2 virus in that country.